Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 14/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.39 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676816 | 1.00 | ADAMTS5 (0.39) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| Hydrochloric Acid SCHEMBL23354761 | 0.98 | ADAMTS5 (0.38) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| Hydrochloric Acid SCHEMBL29979831 | 0.98 | ADAMTS5 (0.38) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| SCHEMBL23366883 | 0.96 | GAA (0.40) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| SCHEMBL23367186 | 0.95 | ADAMTS5 (0.40) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| Hydrochloric Acid SCHEMBL31676812 | 0.95 | GAA (0.39) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| Hydrochloric Acid SCHEMBL23354153 | 0.95 | GAA (0.39) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| Hydrochloric Acid SCHEMBL23354775 | 0.93 | ADAMTS5 (0.39) | ADAMTS5MMP2ADAMTS7TDP1GAA | |
| SCHEMBL24182492 | 0.92 | ADAMTS7 (0.42) | ADAMTS5MMP2ADAMTS7ADAM17ADAMTS4 | |
| SCHEMBL23367036 | 0.92 | ADAMTS7 (0.42) | ADAMTS5MMP2ADAMTS7ADAM17ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | ADAMTS5 4/4885MMP2 108/4885ADAMTS7 1/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | ADAMTS5 7/4885MMP2 137/4885ADAMTS7 1/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | ADAMTS5 7/4885MMP2 137/4885ADAMTS7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.